XHKG
1681
Market cap1.59bUSD
Oct 07, Last price
14.85HKD
1D
-0.54%
1Q
10.66%
Jan 2017
284.72%
IPO
214.62%
Name
Consun Pharmaceutical Group Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Consun Pharmaceutical Group Limited operates as an investment holding company, primarily engaged in the research, development, manufacturing, and distribution of traditional Chinese medicines and sophisticated medical contrast agents throughout the People's Republic of China. The company's operations are structured into two main divisions: Consun Pharmaceutical and Yulin Pharmaceutical. Consun offers a diverse array of pharmaceutical products. For kidney-related conditions, it provides uremic clearance granule for chronic kidney diseases and Yishen Huashi particles to address proteinuria. In the field of medical imaging, the company supplies Gadopentetate Dimeglumine injections, a contrast medium vital for MRI diagnostics of the central nervous system, abdomen, chest, pelvis, and extremities, alongside assessing renal function. Another key imaging agent is Iopamidol injections, utilized in neuroradiology, angiography, and urography. Its extensive portfolio of traditional Chinese medicines includes Zhixueling capsules, effective in managing various bleeding disorders such as uterine bleeding, prolonged lochia, intermenstrual spotting, post-contraceptive ring bleeding, hemorrhoidal bleeding, and epistaxis. Gyn Antidysmenorrheic tablets are offered to alleviate irregular and painful menstruation, including issues experienced during perimenopause due to hepatic depression and blood deficiency. For feminine hygiene, Antibacterial Fujie lotion combats common vaginal infections caused by Staphylococcus aureus, Candida albicans, and Escherichia coli. The company also markets bone-setting liquid and Yunxiang analgesic tincture for a range of ailments including rheumatism, common colds, headaches, stomachaches, chest pain, gastric pain, and chilblains. Additionally, Sanqi Chuangchun capsules are available to enhance blood circulation and reduce stasis, while Shiduqing capsules, tablets, and Paeonol ointment target various skin conditions. The product line is further rounded out with hepatobiliary, gastroenterology, tonic, and other general medicines. Beyond its traditional Chinese remedies and contrast media, the company also markets pharmaceutical products such as Yuanli Kang, an iron-dextrin oral solution; Yibao Yua, an erythromycin estolate suspension; and Yuantong Ning, a cetirizine hydrochloride oral solution. Established in 1997, Consun Pharmaceutical Group Limited is headquartered in Guangzhou, People's Republic of China.
Key people
Meng An
Executive Chairman of the Board and Chief Executive Officer · since 2024
Peicheng Fang
Vice President · since 2025
Yuk Chuen Young
Executive Director · since 2025
Quan Zhu
Executive Director · since 2012
Lanfen Fang
Vice President - Guangzhou Consun · since 2014
Haien Gao
Board Secretary · since 2020
Shangwen Zhou
Director, Vice President - Guangzhou Consun · since 2013
Lihua Zhang
Non-Executive Director · since 2021
Weiwu Duan
Independent Non-Executive Director · since 2025
Zhongshi Feng
Independent Non-Executive Director · since 2013
Zhuoguang Li
Independent Non-Executive Director · since 2025
Yikai Li
Independent Non-Executive Director · since 2024
Legal address
福特街75号邮政信箱1350号
克利夫顿 KY1-0000
KY
克利夫顿 KY1-0000
KY
Headquarters
黄埔区东鹏大道71号
广州市, GD 510735
CN
广州市, GD 510735
CN
Address
P.O.Box 1350,75 Fort Street
Clifton House KY1-0000
KY
Clifton House KY1-0000
KY
Address
71 Dongpeng Street, Huangpu District
Guangzhou, GD 510735
CN
Guangzhou, GD 510735
CN
Other language
CONSUN PHARMACEUTICAL GROUP LIMITED
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||